| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| D-CDX |
|
C85H136N30O25 |
1978.18 |
H2N–GreirtGraerwsekf–OH |
H2N–Gly–DArg–DGlu–DIle–DArg–DThr–Gly–DArg–DAla–DGlu–DArg–DTrp–DSer–DGlu–DLys–DPhe–OH |
16 |
Brain-targeting peptide |
|
| TC6-D3 |
|
C61H98N12O19 |
1303.5 |
H2N–lspLIFVTTPDt–OH |
H2N–DLeu–DSer–DPro–Leu–Ile–Phe–Val–Thr–Thr–Pro–Asp–DThr–OH |
12 |
CCR7-targeting peptide |
|
| Somatostatin-14 |
51110-01-1 / 38916-34-6 |
C76H104N18O19S2 |
1637.88 |
H2N–AGCKNFFWKTFTSC–OH |
H2N–Ala–Gly–Cys–Lys–Asn–Phe–Phe–Trp–Lys–Thr–Phe–Thr–Ser–Cys–COOH |
14 |
|
|
| SGFRKFAS |
|
C41H62N12O11 |
899 |
H2N–SGFRKFAS–OH |
H2N–Ser–Gly–Phe–Arg–Lys–Phe–Ala–Ser–OH |
8 |
3CLpro-targeting peptide |
|
| AS1 |
|
C35H57N11O15S2 |
936.02 |
H2N–CLNSSQPSC–OH |
H2N–Cys–Leu–Asn–Ser–Ser–Gln–Pro–Ser–Cys–OH |
9 |
Microglia and astrocyte–targeting peptide |
|
| MG1 |
|
C36H56N16O13S2 |
985.06 |
H2N–CHHSSSARC–OH |
H2N–Cys–His–His–Ser–Ser–Ser–Ala–Arg–Cys–OH |
9 |
Microglia and astrocyte–targeting peptide |
|
| MG2 |
|
C38H54N10O16S2 |
971.02 |
H2N–CNTGSPYEC–OH |
H2N–Cys–Asn–Thr–Gly–Ser–Pro–Tyr–Glu–Cys–OH |
9 |
Microglia and astrocyte–targeting peptide |
|
| Pep1 |
|
C62H105N25O16 |
1456.66 |
H2N–RPSTTPRVHHIR–OH |
H2N–Arg–Pro–Ser–Thr–Thr–Pro–Arg–Val–His–His–Ile–Arg–OH |
12 |
Adalimumab-specific binding peptide |
|
| PD-L1 inhibitory peptide |
1931111-41-9 |
C96H135N21O23S |
1983.29 |
Ac-Y-(NMeA)-N-P-Dap-L-Hyp-W-Dab-W(CH2COOH)-(NMeNle)-(NMeNle)-L-C-G-Pra |
Ac–Tyr–{NMe-Ala}–Asn–Pro–Dap–Leu–Hyp–Trp–Dab–Trp{CH2COOH}–{NMe-Nle}–{NMe-Nle}–Leu–Cys–Gly–{L-Propargylglycine} |
17 |
PD-L1–targeting peptide |
|
| A3-10 |
|
C77H123N21O24S2 |
1791.06 |
H2N–NPGTCKDKWECLLING–OH |
H2N–Asn–Pro–Gly–Thr–Cys–Lys–Asp–Lys–Trp–Glu–Cys–Leu–Leu–Ile–Asn–Gly–OH |
16 |
TAG-72–targeting peptide |
|
| A2-6 |
|
C64H105N19O25S3 |
1636.83 |
H2N–GGVSCMQTSPVCENNL–OH |
H2N–Gly–Gly–Val–Ser–Cys–Met–Gln–Thr–Ser–Pro–Val–Cys–Glu–Asn–Asn–Leu–OH |
16 |
TAG-72–targeting peptide |
|
| GL1 |
|
C65H98N20O18 |
1447.6 |
H2N–LLADTTHHRPWT–OH |
H2N–Leu–Leu–Ala–Asp–Thr–Thr–His–His–Arg–Pro–Trp–Thr–OH |
12 |
Human glioma–targeting peptide |
|
| TG-1 |
|
C53H86N20O15S2 |
1307.5 |
H2N–MHPNAGHGSLMR–OH |
H2N–Met–His–Pro–Asn–Ala–Gly–His–Gly–Ser–Leu–Met–Arg–OH |
12 |
CD30L-targeting peptide |
|
| Pep42 |
|
C58H94N16O16S2 |
1335.59 |
H2N–CTVALPGGYVRVC–OH |
H2N–Cys–Thr–Val–Ala–Leu–Pro–Gly–Gly–Tyr–Val–Arg–Val–Cys–OH |
13 |
GRP78–targeting peptide |
|
| A5G27 |
|
C77H120N18O17 |
1569.89 |
H2N–RLVSYNGIIFFLK–OH |
H2N–Arg–Leu–Val–Ser–Tyr–Asn–Gly–Ile–Ile–Phe–Phe–Leu–Lys–OH |
13 |
CD44v3 and CD44v6–targeting peptide |
|
| LTVSPWY |
|
C43H60N8O11 |
864.98 |
H2N–LTVSPWY–OH |
H2N–Leu–Thr–Val–Ser–Pro–Trp–Tyr–OH |
7 |
HER2-positive tumor–targeting peptide |
|
| EPPT1 |
|
C84H116N22O22S1 |
1818.02 |
H2N–YCAREPPTRTFAYWG–OH |
H2N–Tyr–Cys–Ala–Arg–Glu–Pro–Pro–Thr–Arg–Thr–Phe–Ala–Tyr–Trp–Gly–OH |
15 |
uMUC-1–targeting peptide |
|
| B18 |
|
C62H109N23O16 |
1432.67 |
H2N–SPRPRHTLRLSL–OH |
H2N–Ser–Pro–Arg–Pro–Arg–His–Thr–Leu–Arg–Leu–Ser–Leu–OH |
12 |
TfR1–positive tissue–targeting peptide |
|
| PP1 |
|
C79H122N22O22S1 |
1764.01 |
H2N–LSLERFLRCWSDAPA–OH |
H2N–Leu–Ser–Leu–Glu–Arg–Phe–Leu–Arg–Cys–Trp–Ser–Asp–Ala–Pro–Ala–OH |
15 |
SR-A–targeting peptide |
|
| P-D2 |
|
C65H98N16O21 |
1439.57 |
H2N–VTLTYEFAAGPRD–OH |
H2N–Val–Thr–Leu–Thr–Tyr–Glu–Phe–Ala–Ala–Gly–Pro–Arg–Asp–OH |
13 |
CD11c-targeting peptide |
|
